Passa al contenuto
Merck

Magnesium sulfate during anticipated preterm birth for infant neuroprotection.

Nursing for women's health (2013-02-13)
Lisa Merrill
ABSTRACT

Advances in medical care of preterm infants, including the widespread use of surfactant and antenatal steroids, and improvements in ventilation management, have increased the survival rates of some of the most vulnerable infants. Yet, the risk of neurologic impairment and long-term medical complications remains a concern. Recently, the use of magnesium sulfate during anticipated preterm birth has been identified as a potential treatment to reduce adverse neurologic outcomes among preterm infants. This article discusses the use of magnesium sulfate for anticipated preterm birth to reduce neurologic impairment in preterm infants, including current clinical practice guidelines and implications for nurses.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Solfato di magnesio, anhydrous, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Solfato di magnesio eptaidrato, ACS reagent, ≥98%
Sigma-Aldrich
Solfato di magnesio eptaidrato, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Solfato di magnesio eptaidrato, BioReagent, for molecular biology, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
Solfato di magnesio, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Solfato di magnesio, puriss. p.a., drying agent, anhydrous, ≥98.0% (KT), powder (very fine)
Sigma-Aldrich
Magnesium sulfate solution, for molecular biology, 1.00 M±0.04 M
Sigma-Aldrich
Solfato di magnesio eptaidrato, BioUltra, ≥99.5% (KT)
Sigma-Aldrich
Magnesium sulfate solution, BioUltra, for molecular biology
Sigma-Aldrich
Solfato di magnesio, ≥99.99% trace metals basis
Sigma-Aldrich
Solfato di magnesio eptaidrato, BioXtra, ≥99.0%